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Summary
Background Although several interventions have shown reduced HIV incidence in clinical trials, the community-level 
eﬀ ect of eﬀ ective interventions on the epidemic when scaled up is unknown. We investigated whether a multicomponent, 
multilevel social and behavioural prevention strategy could reduce HIV incidence, increase HIV testing, reduce HIV 
risk behaviour, and change social and behavioural norms.
Methods For this phase 3 cluster-randomised controlled trial, 34 communities in four sites in Africa and 
14 communities in Thailand were randomly allocated in matched pairs to receive 36 months of community-based 
voluntary counselling and testing for HIV (intervention group) or standard counselling and testing alone (control 
group) between January, 2001, and December, 2011. The intervention was designed to make testing more accessible 
in communities, engage communities through outreach, and provide support services after testing. Randomisation 
was done by a computer-generated code and was not masked. Data were collected at baseline (n=14 567) and after 
intervention (n=56 683) by cross-sectional random surveys of community residents aged 18–32 years. The primary 
outcome was HIV incidence and was estimated with a cross-sectional multi-assay algorithm and antiretroviral drug 
screening assay. Thailand was excluded from incidence analyses because of low HIV prevalence. This trial is registered 
at ClinicalTrials.gov, number NCT00203749.
Findings The estimated incidence of HIV in the intervention group was 1·52% versus 1·81% in the control group 
with an estimated reduction in HIV incidence of 13·9% (relative risk [RR] 0·86, 95% CI 0·73–1·02; p=0·082). HIV 
incidence was signiﬁ cantly reduced in women older than 24 years (RR=0·70, 0·54–0·90; p=0·0085), but not in other 
age or sex subgroups. Community-based voluntary counselling and testing increased testing rates by 25% overall 
(12–39; p=0·0003), by 45% (25–69; p<0·0001) in men and 15% (3–28; p=0·013) in women. No overall eﬀ ect on sexual 
risk behaviour was recorded. Social norms regarding HIV testing were improved by 6% (95% CI 3–9) in communities 
in the intervention group.
Interpretation These results are suﬃ  ciently robust, especially when taking  into consideration the combined results of 
modest reductions in HIV incidence combined with increases in HIV testing and reductions in HIV risk behaviour, 
to recommend the Project Accept approach as an integral part of all interventions (including treatment as prevention) 
to reduce HIV transmission at the community level. 
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Introduction
Several interventions have led to reduced HIV incidence in 
clinical trials, including early treatment of HIV infec tion,1,2 
use of antiretroviral therapy to prevent mother-to-child 
transmission,3,4 chemoprophylaxis,5,6 and male circum ci s-
ion.7–9 The challenge is to show community-level eﬀ ects on 
the epidemic when eﬀ ective interventions are scaled up.10
NIMH Project Accept (HPTN 043) was the ﬁ rst cluster-
randomised trial to test whether a theory-based, 
multicomponent, multilevel social and behavioural 
prevention strategy could reduce HIV incidence within 
entire communities. The study hypothesis was that 
community-based voluntary counselling and testing for 
HIV compared with standard voluntary counselling and 
testing would improve community norms about testing, 
reduce risk behaviours, reduce stigma about HIV, 
promptly link individuals with HIV to available services, 
and decrease disease incidence. A major goal of the 
intervention was to reduce logistical barriers to HIV 
testing. The intervention was designed to adapt 
dynamically to changes arising in the communities with 
real-time performance feedback.
We have previously reported the baseline characteristics 
of the study population11 and methods and uptake of the 
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intervention.12 At three trial sites, more HIV tests were 
done and more HIV infections were newly detected in 
communities with community-based voluntary 
counselling and testing than in communities with the 
standard intervention.
We report ﬁ ndings of the analysis of HIV incidence, 
the primary outcome of Project Accept, and those of 
secondary social and behavioural outcomes. All outcomes 
were assessed at the community level, irrespective of 
participation in the intervention.
Methods
Study design and participants
Project Accept was a cluster-randomised trial done in 
34 communities at four sites in Africa (Soweto and 
KwaZulu-Natal, South Africa; Tanzania; and Zimbabwe) 
and in 14 communities in Thailand between January, 
2001, and December, 2011. Baseline demographic, 
behavioural, and social data were collected from a 
random sample of community residents aged between 
18 and 32 years,11 followed by community randomisation 
and a 36-month intervention.13 Eligibility criteria for 
participation in the baseline assessment and post-
intervention assessment were: age 18–32 years, present 
residency in the community, and ability to provide 
informed consent. Participation in all intervention 
activities and services was open to all individuals aged 
16 years and older. The eﬀ ect of the study intervention 
was assessed across entire communities in one cross-
sectional survey done at the end of the intervention. The 
study protocol, operation manuals, and standard 
operating procedures are publicly available.14 Figure 1 
shows a timeline for the study.
The trial was done in close partnership with established 
community advisory boards and local government 
departments. Oral consent was obtained at the community 
level for trial participation and randomisation. 
Participation in all intervention activities was voluntary. To 
approach household members to participate in the post-
intervention assessment, investigators needed permission 
from the head of the household. Oral consent was 
obtained from each participant for each component of 
data collection and for collection and testing of blood 
samples. The study was approved by ethics committees 
for each site and by all participating academic institutions.
Randomisation and masking
The communities in each site were located in 
geographical areas with deﬁ ned boundaries.11 At the 
African sites, the communities were close, but in most 
cases were not immediately adjacent to each other. The 
population size of communities varied from 5000 to 15 000 
at four sites; at the Soweto site, the typical population 
size was between 15 000 and 25 000.
The communities were matched into pairs before 
randomisation on the basis of sociodemographic, cultural, 
and infrastructure characteristics established by formative 
research.15,16 Within each pair, one community was 
randomly assigned to receive community-based voluntary 
counselling and testing, the other received standard 
voluntary counselling and testing alone. Randomisation 
was done centrally by a sequence of random numbers 
generated by the Mersenne-Twister random number 
generator implemented in R. The seed was derived from 
the system time recorded at the moment the randomisation 
was done. The randomisation code was  written and run by 
the protocol statistician at the Statistical Centre at Charles 
University in Prague, Czech Republic.17 Because of the 
nature of the intervention, the assignment was not 
masked, except at the laboratories that analysed study 
samples (the laboratory staﬀ  were unaware of intervention 
assignment of individual communities). 
Procedures
The community-based voluntary counselling and testing 
intervention was designed to change the context in which 
individuals and communities respond to HIV with four 
main components.13 The community mobilisation 
component used outreach coordinators and early testers 
as outreach workers to modify norms for HIV testing, 
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Pilot studies in Zimbabwe and Thailand Baseline survey
Intervention
Qualitative cohort
Post-intervention
assessment
Community selection, 
recruitment, funding
• Probability sample of 
 individuals aged 18–32 years
• Survey only
Community 
randomisation
• Assessment of a random sample of individuals 
 aged 18–32 years in each intervention and 
 control community
• Behavioural survey 
• Biological assays to estimate HIV incidence
Figure 1: Study timeline
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encourage discussion about HIV testing and disclosure of 
HIV status, increase uptake of testing, and reduce stigma. 
The easy access to voluntary counselling and testing 
component was designed to increase awareness of HIV 
status through easily accessible voluntary counselling and 
testing services provided in mobile units. The post-test 
support services component provided peer-based social 
support groups for those who had been tested, irrespective 
of test results. Topics included, for example, social beneﬁ ts 
and harms, status disclosure, access to HIV-related 
services, advances in HIV treatment, and risk of HIV 
transmission. The real-time performance feedback 
component ensured that pre-set intervention goals were 
met (appendix p 1).13 Standard voluntary counselling and 
testing consisted of services at existing district hospitals or 
local health-care facilities, which were also available in 
communities with the community-based intervention. 
The intervention and its adaptation to various settings 
have been described elsewhere.13,18–20
Data were collected in random samples of community 
residents, irrespective of their participation in 
intervention activities. The baseline assessment was 
done before randomisation and did not include HIV 
testing.11 The post-intervention assessment was 
independent of the baseline assessment. Households 
were selected with equal probability from a complete 
listing of community households. At baseline, one 
eligible individual was randomly selected from each 
household to provide detailed demographic and 
behavioural data. At the post-intervention assessment, all 
eligible individuals from the selected households were 
invited to participate in a brief survey and collection of 
blood samples. In a random subsample of all the 
households, one eligible participant was randomly 
selected to complete a detailed demographic and 
behavioural questionnaire (appendix p 2).
Study implementation was supervised and managed by 
principal investigators and project managers at the study 
sites. A steering committee of 11 members had a 
conference call every month, and met in person twice a 
year to design and approve all study procedures, monitor 
study progress, and approve all modiﬁ cations and study 
publications. The NIMH constituted a Data and Safety 
Monitoring Board and Study Monitoring Committee that 
convened twice a year to ensure that all study objectives 
were being met and that the safety of study participants 
was not compromised. Real-time performance feedback 
was provided every month to each study team to ensure 
that study objectives were being met.
Outcomes
The primary outcome of Project Accept was HIV 
incidence. Secondary outcomes were social and 
behavioural: sexual risk behaviour, HIV testing rates, 
social norms regarding testing, discussions about HIV, 
disclosure of HIV status, stigma associated with HIV, 
and HIV-related negative life events.
HIV incidence was assessed by analysis of cross-
sectional samples collected during the post-intervention 
assessment. Samples were tested in-country with HIV 
rapid tests; details of testing are reported by Laeyendecker 
and colleagues.21 The ﬁ nal HIV status of study participants 
was established at the HPTN Network Laboratory at Johns 
Hopkins University (MD, USA).21 HIV incidence was 
assessed with a multi-assay algorithm  that included the 
BED capture immunoassay, an antibody avidity assay, 
CD4 cell count (obtained at study sites), and HIV viral load 
(obtained at the HPTN Network Laboratory for a subset of 
samples).21 The algorithm was developed and validated 
with data obtained for 4166 samples from 2882 individuals 
with known duration of infection (from 1 month to 
>10 years) from seven African cohorts.22 It was optimised 
to detect a diﬀ erence in HIV incidence between southern 
African populations. An antiretroviral drug screening 
assay was used to exclude individuals on antiretroviral 
therapy from the incidence assessment.21 Early and acute 
infections were identiﬁ ed with testing algorithms that 
included serological and HIV RNA assays. 21
Behavioural outcome measures were assessed with 
questionnaires administered by interviewers. HIV 
testing uptake was assessed as the proportion of 
participants who reported at least one HIV test during 
the past 12 months. In the post-intervention assessment, 
testing in the previous 36 months was also assessed. The 
social norms score was calculated as the mean of scores 
(ranging from 0 to 3 on a Likert scale) of the participant’s 
responses to six statements assessing their opinion on 
prevailing community attitudes towards HIV testing 
(a higher value is associated with more positive 
attitudes). HIV behaviour risk score was assessed with 
self-reports of monthly number of unprotected sexual 
acts averaged during the past 6 months. Number of 
sexual partners was also recorded in subanalyses. 
Individuals who were not sexually active in the past 
6 months were assigned a score of zero. Negative life 
events were assessed as the proportion of participants 
who reported any events related to partnership break-up, 
discrimination, estrangement, neglect, or violence. 
Discussions about HIV were measured by the proportion 
of participants who reported having any HIV-related 
conversation in the past 6 months. Disclosure of HIV 
status was measured as the proportion of tested 
participants who disclosed their HIV test results to 
another person. HIV stigma score was calculated as the 
mean of scores (on a 0 to 4 point Likert scale) assigned to 
validated 28 stigma-related scale items.23,24 A higher score 
was associated with more stigma.
Protocol changes
During the study, several unexpected events warranted 
changes in the protocol. First, one community pair in 
Soweto was removed from the study soon after the start 
of the intervention because of threats of political violence. 
This community pair was replaced by another; a separate 
See Online for appendix
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randomisation was done for the new pair and all study 
activities were undertaken as outlined. Data from the 
withdrawn community pair were not included in any 
analyses. Second, the original study plan was to establish 
the primary HIV incidence outcome with BED capture 
immunoassay alone. The laboratory plan was revised 
because of serious concerns about the validity of this 
approach.25 Third, the HIV prevalence in the 14 Thai 
communities was very low (about 1%). Therefore, the 
incidence assessment was restricted to the 34 African 
communities. Fourth, ﬁ ndings of quality assurance 
testing showed that some stored samples from the 
Soweto site were cross-contaminated,21 and could not be 
assessed at the HPTN Network Laboratory.
Statistical analysis
The sample size (seven pairs in Thailand with 
500 assessment participants per community; ﬁ ve pairs in 
Tanzania with 900 assessment participants per 
community; four pairs at the other sites with 
1430 assessment participants per community) was 
calculated by an adaptation of methods suggested by 
Hayes and Bennett26 to provide 80% power to detect a 
35% reduction in HIV incidence. The assumptions 
behind the sample size calculation were 30% prevalence, 
3% annual incidence, follow-up duration of 6 months, no 
misclassiﬁ cation of incident infections, and coeﬃ  cient of 
variation 0·26. The power was recalculated after HIV 
prevalence in the communities was established, and the 
testing algorithm used for the HIV incidence assessment 
was developed and validated. With a weighted t test, the 
study provided more than 90% power to detect a 35% 
reduction in HIV incidence.
The intervention eﬀ ect for each community pair was 
calculated as a log incidence ratio for the intervention 
versus the control group. The overall intervention eﬀ ect 
was estimated by the weighted mean of pair-speciﬁ c 
eﬀ ects; the weights were proportional to the harmonic 
mean of the number of incident infections recorded in the 
paired communities. The  weighted paired t test was used 
to test the hypothesis of no intervention eﬀ ect at the two-
sided level of 5%. CIs were based on the weighted paired 
t statistic. The number of degrees of freedom of the 
reference t distribution was adjusted to take into account 
unequal weights (the primary analysis used 9·4 degrees of 
freedom in 17 pairs). The approximate degrees of freedom 
were calculated as the inverse of the sum of squared 
weights minus 1 (if the weights were all equal, this yielded 
a degree of freedom of 16 for the classic t test; the test is 
asymptotic). We veriﬁ ed via simulations that the 
t distribution with approximated degrees of freedom 
provided better results in small samples (correct level and 
correct CI coverage) than did the t distribution used with 
the classic t test or the limiting standard normal 
distribution. Subgroup analyses by age and sex were done 
with the same methods on a subset of the data; these 
analyses were prespeciﬁ ed in the protocol.
For each behavioural outcome, community-speciﬁ c 
means were calculated at baseline (if available) and in the 
post-intervention assessment. For the outcomes that were 
measured on one randomly selected household member, 
the means were weighted by inverse sampling 
probabilities to adjust for an increased chance of inclusion 
of participants living in smaller households. Intervention 
eﬀ ects were tested with unweighted paired t tests on logs 
of ratios of post-intervention assessment community 
means to baseline community means. This approach 
adjusted the intervention eﬀ ect for baseline diﬀ erences 
between the communities. When the baseline mean was 
not available (36 month testing rates) or baseline data 
were too sparse (12 month testing rates), the test was 
done on log post-intervention assessment means only 
(unadjusted for baseline). Estimates of overall and site-
speciﬁ c means and intervention eﬀ ects were obtained by 
exponentiation of averages of community-speciﬁ c means 
and intervention eﬀ ects calculated on the log scale. Two-
sided CIs were based on the t distribution on the log 
scale. Subgroup analyses were done by sex, for selected 
outcomes, and by HIV status, which was established by 
in-country HIV rapid testing.
This trial is registered at ClinicalTrials.gov, number 
NCT00203749.
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
50 communities were enrolled, matched into pairs, and 
randomly assigned to the intervention or control group; 
48 of the communities received the assigned intervention 
Figure 2: Trial proﬁ le
CBVCT=community-based voluntary counselling and testing. SVCT=standard voluntary counselling and testing. 
*One community (Soweto) was withdrawn shortly after the initiation of the intervention and replaced. †Seven 
Thai communities excluded because of low prevalence.
50 communities in 25 pairs randomised
25 communities allocated to CBVCT 25 communities allocated to SVCT
24 communities completed intervention* 24 communities completed intervention*
24 communities completed 
 post-intervention assessment
17 communities 
 analysed
 (primary)†
24 communities 
 analysed
 (secondary)
17 communities 
 analysed
 (primary)†
24 communities 
 analysed
 (secondary)
24 communities completed 
 post-intervention assessment
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and post-intervention assessment (ﬁ gure 2). Because of 
low HIV prevalence in the Thai site, only the 34 African 
communities were included in the primary endpoint 
analysis (ﬁ gure  2). All 48 communities participated in 
secondary outcome analyses.
Table 1 shows the size of the community populations in 
the post-intervention assessment. Baseline characteristics 
have been described elsewhere.11 During the intervention, 
study teams organised 15 603 community mobilisation 
activities, provided 71 842 voluntary counselling and 
testing sessions, and 51  787 support service sessions after 
testing. The appendix describes the participant ﬂ ow 
through the baseline assessment and post-intervention 
assessment (appendix p 2). Of 84 947 potential housing 
structures visited during the post-intervention assess-
ment, 9535 (11%) were non-residential (eg, business, 
storage, or animal structures). 34 828 (41%) households 
included no eligible participants. The appendix 
summarises response rates for the primary outcome 
assessment (appendix). In African sites, nearly 
60 000 potentially eligible participants lived in the 
selected households (appendix p 3). Of them, 8% could 
not be contacted, 4% refused participation, and 6% were 
ineligible (appendix). In eligible participants, the 
response rate for blood sample collection was 94%. When 
failure to contact participants was taken into account, the 
Thailand Zimbabwe Tanzania KwaZulu-Natal Soweto
CBVCT (N=7) SVCT (N=7) CBVCT (N=4) SVCT (N=4) CBVCT (N=5) SVCT (N=5) CBVCT (N=4) SVCT (N=4) CBVCT (N=4) SVCT (N=4)
Site population (all ages) 55 100 48 100 45 200 48 200 27 500 27 400 33 600 33 600 85 900 66 100
Community population 
(all ages) 
7900 
(4900–10 900)
6900
(6300–7600)
11 300
(10 100–12 500)
12 000 
(8600–15 800)
5500 
(3600–7700)
5500 
(3400–6400)
8400 
(7000–9400)
8400 
(7700–9100)
21 500 
(16 600–24 400)
16 500 
(5100–23 900)
Site population 
(age 18–32 years)
9200 6600 10 100 11 000 6000 5700 9800 9500 27 900 20 100
Community population 
(age 18–32 years) 
1300 
(800–2100)
900 
(800–1200)
2500 
(2200–2900)
2700 
(1900–3800)
1200 
(700–1600)
1100 
(700–1300)
2400 
(2100–3000)
2400 
(2100–2500)
7000 
(5300–10 100)
5000 
(1500–7300)
Number of households 
per community (range)
2471 
(1626–3276)
2223 
(1910–2478)
2888 
(2605–3189)
3024 
(2233–3712)
1570 
(950–1949)
1587 
(881–1920)
2588 
(2306–2900)
2604 
(1801–3134)
4665 
(3395–6178)
3642 
(1649–5263)
Median household size 3 3 4 4 4 4 4 4 4 4
Data are mean (range) unless otherwise stated. CBVCT=community-based voluntary counselling and testing. SVCT=standard voluntary counselling and testing. 
Table 1: Characteristics of the participating communities in the post-intervention assessment
Thailand Zimbabwe Tanzania KwaZulu-Natal Soweto African sites (total)
CBVCT SVCT CBVCT SVCT CBVCT SVCT CBVCT SVCT CBVCT SVCT CBVCT SVCT
Initial HIV status (rapid testing)
Negative 3727 (98%) 3775 (99%) 5126 (87%) 5187 (87%) 4284 (92%) 4028 (92%) 4041 (68%) 4107 (69%) 6116 (87%) 5806 (84%) 19 567 (83%) 19 128 (83%)
Positive 44 (1%) 34 (1%) 788 (13%) 760 (13%) 290 (6%) 252 (6%) 1851 (31%) 1798 (30%) 874 (13%) 1111 (16%) 3803 (16%) 3921 (17%)
Discordant 16 (0%) 23 (1%) 9 (0%) 10 (0%) 110 (2%) 77 (2%) 21 (0%) 25 (0%) 8 (0%) 14 (0%) 148 (1%) 126 (1%)
Final HIV status
Uninfected 3743 (99%) 3797 (99%) 5146 (87%) 5202 (87%) 4400 (94%) 4105 (94%) 4063 (69%) 4134 (70%) 6134 (88%) 5828 (84%) 19 743 (84%) 19 269 (83%)
Infected* 44 (1%) 35 (1%) 777 (13%) 755 (13%) 284 (6%) 252 (6%) 1850 (31%) 1795 (30%) 712 (10%) 941 (14%) 3623 (15%) 3743 (16%)
Unknown† 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (0%) 152 (2%) 162 (2%) 152 (1%) 163 (1%)
Multi-assay algorithm status (in samples classiﬁ ed as HIV postive)
Negative 43 (98%) 33 (94%) 750 (97%) 711 (94%) 251 (88%) 228 (91%) 1733 (94%) 1667 (93%) 668 (94%) 879 (93%) 3402 (94%) 3485 (93%)
Positive, acute, 
and early infections
1 (2%) 2 (6%) 27 (4%) 43 (6%) 33 (12%) 24 (10%) 115 (6%) 127 (7%) 44 (6%) 61 (7%) 219 (6%) 255 (7%)
Not assessed* 0 (0%) 0 (0%) 0 (0%) 1 (0%) 0 (0%) 0 (0%) 2 (0%) 1 (0%) 0 (0%) 1 (0%) 2 (0%) 3 (0%)
Results of antiretroviral drug testing (in samples classiﬁ ed as multi-assay algorithm positive, acute infection, or early infection)
Antiretroviral 
drugs detected
0 (0%) 0 (0%) 2 (7%) 1 (2%) 6 (18%) 4 (17%) 5 (4%) 7 (6%) 1 (2%) 3 (5%) 14 (6%) 15 (6%)
No antiretroviral 
drugs detected‡
1 (100%) 2 (100%) 25 (93%) 42 (98%) 27 (82%) 20 (83%) 110 (96%) 120 (95%) 43 (98%) 58 (95%) 205 (94%) 240 (94%)
CBVCT=community-based voluntary counselling and testing. SVCT=standard voluntary counselling and testing. *Five of the 7366 participants who were conﬁ rmed as HIV-positive were excluded from the 
incidence analysis because of missing CD4 cell count data (not assessed by the multi-assay algorithm). †315 participants who had at least one reactive HIV rapid test were excluded from the analysis because it 
was not possible to conﬁ rm their HIV status. This number included 292 participants who were excluded because of sample contamination and 23 participants who were excluded for other reasons.21 ‡This group 
includes samples from participants with acute and early HIV infection (those samples were not tested for the presence of antiretroviral drugs) and samples that did not have enough plasma remaining for 
antiretroviral testing.21
Table 2: Blood sample analysis
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overall response rate was 82%. We recorded no signiﬁ cant 
diﬀ erence in the response rate by study group.
The post-intervention assessment included a large 
proportion of the whole community population (29% of 
all eligible participants in Soweto and 57–77% of all 
eligible participants in the other three African sites).
Table  2 summarises the results of the blood sample 
analyses. 46 693 blood samples were collected; 320 (1%) 
of samples were excluded from incidence assessment 
(table 2). The HIV incidence analysis included data from 
39 012 HIV-negative participants and 7361 HIV-positive 
participants enrolled at the African sites.21 445 samples 
were classiﬁ ed as potentially incident infections21 and 
formed the basis of the HIV incidence analysis (205 in 
the community group and 240 in the standard testing 
group); these samples included acute and early infections 
and multi-assay algorithm positive samples in which 
antiretroviral drugs were not detected.
Table 3 shows the demographic and behavioural 
characteristics of the 46 378 study participants with 
known ﬁ nal HIV status. On average, 54% of these 
participants were women and a slight majority of men 
and women were 18–24 years old. On average, the 
South African sites had more years of education and 
lower marriage levels than did the other sites in Africa 
(table 3).
Table 4 shows site-speciﬁ c HIV prevalence results. 
The overall HIV prevalence in the African sites was 
16·5%. The highest HIV prevalence was recorded in 
KwaZulu-Natal (table  4); at this site 31% of all 
participants, more than 50% of participants aged 
25–32 years, and more than 60% of women aged 
25–32 years were HIV positive (table 4). The other sites 
had lower HIV prevalence (table 4). At all sites, HIV 
prevalence in women was more than double that in 
men, and HIV prevalence in the older age group 
(25–32 years) was about three times higher than in the 
younger age group (18–24 years; table 4).
HIV incidence was 1·52% in the intervention groups 
and 1·81% in the control groups—a borderline 
signiﬁ cant overall diﬀ erence of 14% (table 5). The 
reduction in incidence in women and men was not 
signiﬁ cant (table 5). Little change in incidence was 
recorded in the younger age group (RR=0·98); the older 
age group had a 25% reduction (table 5). The 
intervention eﬀ ect was signiﬁ cant in women in the 
older age group (table 5).
We repeated the analysis with a more stringent multi-
assay algorithm, and with a standard paired t test rather 
than a weighted t test, and noted very similar intervention 
eﬀ ects, but with larger standard errors and wider 
conﬁ dence intervals (data not shown).
Overall, the intervention seemed to reduce incidence at 
all sites except Tanzania (table 5). The reduction was 
quite small in KwaZulu-Natal, the site with the highest 
HIV incidence. In KwaZulu-Natal, the intervention did 
Thailand Zimbabwe Tanzania KwaZulu-Natal Soweto African sites (total)
CBVCT 
(n=3787)
SVCT 
(n=3832)
CBVCT 
(n=5923)
SVCT 
(n=5957)
CBVCT 
(n=4684)
SVCT 
(n=4357)
CBVCT 
(n=5913)
SVCT 
(n=5929)
CBVCT 
(n=6846)
SVCT 
(n=6769)
CBVCT 
(n=23 366)
SVCT 
(n=23 012)
Sex
Men 1947 (51%) 1960 (51%) 2826 (48%) 2924 (49%) 2143 (46%) 2016 (46%) 2483 (42%) 2488 (42%) 3143 (46%) 3159 (47%) 10 595 (45%) 10 587 (46%)
Women 1840 (49%) 1871 (49%) 3094 (52%) 3033 (51%) 2541 (54%) 2340 (54%) 3420 (58%) 3428 (58%) 3698 (54%) 3607 (53%) 12 753 (55%) 12 408 (54%)
Age (men)
18–24 years 925 (48%) 926 (47%) 1465 (52%) 1530 (52%) 936 (44%) 858 (43%) 1636 (67%) 1665 (68%) 1685 (54%) 1802 (57%) 5722 (54%) 5855 (56%)
25–32 years 1022 (53%) 1033 (53%) 1360 (48%) 1392 (48%) 1205 (56%) 1157 (57%) 815 (33%) 796 (32%) 1454 (46%) 1352 (43%) 4834 (46%) 4697 (44%)
Age (women)
18–24 years 851 (46%) 853 (46%) 1467 (48%) 1471 (49%) 1129 (44%) 986 (42%) 2006 (59%) 2039 (60%) 1894 (51%) 1951 (54%) 6496 (51%) 6447 (52%)
25–32 years 988 (54%) 1018 (54%) 1624 (53%) 1560 (52%) 1411 (56%) 1353 (58%) 1383 (41%) 1361 (40%) 1803 (49%) 1650 (46%) 6221 (49%) 5924 (48%)
Education
<5 years 1299 (34%) 794 (21%) 160 (3%) 173 (3%) 1,066 (23%) 1,071 (25%) 121 (2%) 132 (2%) 54 (1%) 60 (1%) 1401 (6%) 1436 (6%)
5–8 years 781 (21%) 787 (21%) 1456 (25%) 1413 (24%) 2788 (60%) 2693 (62%) 388 (7%) 503 (9%) 245 (4%) 241 (4%) 4877 (21%) 4850 (21%)
9–12 years 1423 (38%) 1811 (47%) 3932 (67%) 3976 (67%) 781 (17%) 547 (13%) 5098 (86%) 4971 (84%) 5295 (78%) 5143 (76%) 15 106 (65%) 14 637 (64%)
>12 years 284 (8%) 439 (12%) 366 (6%) 387 (7%) 46 (1%) 41 (1%) 293 (5%) 299 (5%) 1235 (18%) 1305 (19%) 1940 (8%) 2032 (9%)
Marital status
Single 1045 (28%) 1299 (34%) 1895 (32%) 1849 (31%) 1938 (41%) 1687 (39%) 5730 (98%) 5744 (98%) 6085 (89%) 6200 (92%) 15 648 (67%) 15 480 (68%)
Married 2411 (64%) 2201 (57%) 3381 (57%) 3522 (59%) 2436 (52%) 2378 (55%) 131 (2%) 127 (2%) 677 (10%) 509 (8%) 6625 (28%) 6536 (29%)
Separated 329 (9%) 332 (9%) 641 (11%) 577 (10%) 310 (7%) 287 (7%) 11 (0%) 15 (0%) 54 (1%) 39 (1%) 1016 (4%) 918 (4%)
Sexual activity in the past 6 months
Active 2770 (83%) 2673 (81%) 4088 (80%) 4208 (80%) 3146 (73%) 3087 (76%) 3767 (74%) 3558 (71%) 5073 (80%) 4963 (80%) 16 074 (77%) 15 816 (77%)
CBVCT=community-based voluntary counselling and testing. SVCT=standard voluntary counselling and testing.
Table 3: Demographic and behavioural characteristics in participants with known ﬁ nal HIV status
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not reduce HIV incidence in the younger subgroup or in 
all women, but in the older subgroup of women incidence 
was reduced by more than 40%.
The intervention increased HIV testing uptake 
signiﬁ cantly, and was especially eﬀ ective in increasing 
testing in men. Overall 12-month testing rates were 25% 
higher in the intervention group than in the control group 
(table 6). The largest eﬀ ect on testing uptake was recorded 
in Thailand (56%; appendix p 4). Testing rates during 
36 months were 27% higher in the intervention group 
(table 6). Overall, 49% of the entire 18–32-year-old 
population living in communities with community-based 
voluntary counselling and testing was tested during the 
study, compared with 39% in communities with standard 
voluntary counselling and testing.
Annual testing rates in men reached 16% after the 
intervention in the control group, and 24% in the 
intervention group (table  6), showing a 45% increase 
over the control group (table 6). At baseline, 12-month 
testing rates in women were more than twice as large as 
in men, probably because of antenatal testing. After the 
interventions were concluded, testing rates in women 
increased to 34% (control group) and 39% (intervention 
group), which corresponds to a 15% intervention eﬀ ect 
on testing (p=0·0134). Of the individual sites, only 
Thailand had a meaningful eﬀ ect on testing in women 
(appendix p 5). Soweto was the only site that did not 
show a clear eﬀ ect on testing rates in men (appendix p 5).
The intervention had a signiﬁ cant eﬀ ect on community 
social norms for HIV testing (table 6 and appendix p 6). 
The mean social norms score was 6% higher in 
communities with community-based voluntary 
counselling and testing than in the communities with 
standard voluntary counselling and testing after 
adjustment for baseline diﬀ erences (table 6). The positive 
change in social norms was greater in men (8% increase) 
than in women (4% increase), but the intervention eﬀ ect 
was signiﬁ cant in both subgroups.
We recorded no eﬀ ect on sexual risk behaviour 
measured by the number of unprotected sexual acts 
(table 6 and appendix p 7). However, in individuals with 
HIV, a signiﬁ cant reduction of high-risk sexual 
behaviour was noted in the intervention group. The 
number of sexual partners of HIV-positive participants 
was reduced by 8% (95% CI 1–15; p=0·034), and HIV-
positive men reduced the number of partners by 18% 
(95% CI 5–28; p=0·009). Additionally, the proportion of 
HIV-infected participants reporting multiple partners in 
the 6 months before interview was 30% lower in the 
intervention communities than in the control 
communities (95% CI 8–46; p=0·014). This eﬀ ect was 
stronger in men with HIV than in those without; 36% of 
men with HIV in the control communities reported 
multiple partners compared with 26% in the intervention 
communities (29% reduction; 95% CI 11–43; p=0·006). 
Self-reported multiple partnerships were rare in HIV-
positive women.
The intervention did not aﬀ ect the proportion of 
participants who reported having had negative life events 
or having a conversation about HIV in the past 6 months 
(table 6). About 80–90% of participants who were tested for 
HIV reported disclosing their status to at least one person 
and the proportion did not vary by intervention group 
(table 6). HIV-related stigma was also not aﬀ ected by 
intervention. Baseline mean stigma scores were low, with 
slight decreases at assessment after intervention (table 6).
Discussion
Findings of Project Accept showed that a multicomponent, 
multilevel social and behavioural intervention can produce 
slight reductions in HIV incidence, especially in older 
women (aged 25–32 years; panel). The intervention did not 
decrease HIV incidence in young people (aged 18–24 years) 
or older men. The 30% reduction in HIV incidence in 
older women was consistent in nearly all community pairs 
and was highly signiﬁ cant. The intervention improved 
Prevalence (%)* Number of 
incident samples†
Incidence‡ Eﬀ ect§ Site weight 
(%)¶
CBVCT SVCT CBVCT SVCT CBVCT SVCT
All participants
Zimbabwe 13·1% 12·7% 25 42 0·68% 1·13% 0·63 13·9%
Tanzania 6·1% 5·8% 27 20 0·86% 0·68% 1·23 10·1%
KwaZulu-Natal 31·3% 30·3% 110 120 3·76% 4·03% 0·93 53·8%
Soweto 12·3% 15·9% 43 58 1·18% 1·63% 0·74 22·2%
Women
Zimbabwe 17·5% 17·4% 15 27 0·83% 1·51% 0·55 13·2%
Tanzania 8·1% 8·2% 22 16 1·32% 1·05% 1·18 10·9%
KwaZulu-Natal 40·9% 39·0% 77 75 5·26% 4·96% 1·06 53·2%
Soweto 17·3% 22·4% 28 43 1·53% 2·38% 0·67 22·8%
Men
Zimbabwe 8·3% 7·7% 10 15 0·54% 0·78% 0·99 15·5%
Tanzania 3·6% 3·0% 5 4 || || || 4·9%
KwaZulu-Natal 18·0% 18·3% 33 45 2·26% 3·08% 0·73 61·5%
Soweto 6·4% 8·4% 15 15 0·82% 0·84% 0·89 18·1%
Age 18–24 years
Zimbabwe 5·8% 5·7% 7 19 0·36% 0·94% 0·41 7·8%
Tanzania 2·4% 2·3% 8 4 || || || 3·3%
KwaZulu-Natal 18·7% 18·9% 90 79 4·21% 3·65% 1·14 69·4%
Soweto 6·1% 8·2% 20 32 1·08% 1·52% 0·72 19·5%
Age 25–32 years
Zimbabwe 20·3% 19·7% 18 23 1·06% 1·36% 0·87 21·0%
Tanzania 8·9% 8·3% 19 16 1·12% 0·98% 1·10 19·7%
KwaZulu-Natal 52·7% 50·1% 20 41 2·68% 5·26% 0·51 32·0%
Soweto 19·1% 25·4% 23 25 1·38% 1·79% 0·79 27·3%
CBVCT=community-based voluntary counselling and testing. SVCT=standard voluntary counselling and testing. 
*HIV prevalence of population. †The number of samples from HIV-positive individuals that were classiﬁ ed as 
multi-assay algorithm positive (excluding samples with antiretroviral drugs detected), and samples from HIV-positive 
individuals with acute or early infection. ‡Annual rate, calculated across the whole site. §Relative risk of HIV infection 
(CBVCT vs SVCT); weighted average of incidence ratios across community pairs at the site. ¶Percentage contribution of 
the site to the overall weighted analysis. ||Not enough incident samples to calculate incidence reliably.
Table 4: Site-speciﬁ c incidence results for all participants and by sex and age
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HIV testing rates in the peak age range for HIV infection 
(18–32 years), especially in men; increased the number of 
people who knew their HIV status; and reduced HIV risk 
behaviours in people with HIV who might otherwise have 
transmitted the virus to others. The eﬀ ectiveness of the 
intervention was tested in all community residents within 
the selected age range rather than only in individuals who 
directly participated in intervention activities.
We do not know why the intervention did not reduce 
HIV incidence in young people and why most of the eﬀ ect 
was concentrated in older women. Possible reasons are 
the exclusion of Thailand from the analysis, insuﬃ  cient 
penetration of the intervention in key HIV-1 transmission 
groups, and insuﬃ  cient provision of services (eg, active 
referral to and maintenance in treatment). The most 
important behavioural change was reported in HIV-
infected men, who reduced the number of sexual partners 
and occurrence of multiple partnerships. This change 
could protect the main partners of these men, most likely 
women older than 25 years. However, a more in-depth 
analysis is needed to verify this hypothesis. During the 
trial, antiretroviral therapy (ART) became widely available 
at most sites. The increased testing rates in intervention 
communities should have improved treatment coverage 
and led to reduced incidence. However, the duration of the 
ART availability during the trial might have been too short 
to see community-wide reduction in incidence resulting 
from increased ART uptake. A laboratory assessment is 
planned to assess ART uptake and to investigate the 
possible role of treatment in the intervention eﬀ ect.
This is the ﬁ rst documentation that we could ﬁ nd of a 
programme that reaches men, increases their HIV 
testing, and reduces their risk behaviour more than in 
women. We believe that the increased testing in men 
compared with women was attributable to more than the 
higher baseline in women because of more frequent use 
of the health-care system and thus more routine testing. 
Increasingly, evidence suggests that men in sub-Saharan 
Africa are less likely to access testing, and more likely to 
Baseline assessment Post-intervention assessment
Mean outcome 
in CBVCT 
communities
Mean outcome 
in SVCT 
communities
Ratio* Mean outcome 
in CBVCT 
communities
Mean outcome 
in SVCT 
communities
Eﬀ ect† (95% CI) p value‡
12-month testing uptake 0·14 0·16 0·87 0·32 0·26 1·25 (1·12–1·39) 0·0003
Men 0·09 0·08 1·13 0·24 0·16 1·45 (1·25–1·69) <0·0001
Women 0·19 0·22 0·86 0·39 0·34 1·15 (1·03–1·28) 0·013
36-month testing uptake NA NA NA 0·49 0·39 1·27 (1·15–1·41) <0·0001
Men NA NA NA 0·37 0·25 1·48 (1·29–1·69) <0·0001
Women NA NA NA 0·59 0·50 1·17 (1·07–1·29) 0·0019
Sexual risk behaviour 3·97 3·76 1·06 4·39 4·27 0·97 (0·89–1·06) 0·53
Social norms regarding testing 1·26 1·25 1·01 1·38 1·29 1·06 (1·03–1·09) 0·0001
Discussions about HIV 0·46 0·46 0·99 0·39 0·39 1·03 (0·92–1·16) 0·56
Disclosure of HIV status 0·81 0·83 0·98 0·87 0·89 0·98 (0·95–1·02) 0·29
HIV-related stigma 1·39 1·37 1·02 1·22 1·21 0·99 (0·96–1·03) 0·74
Negative life events 0·30 0·29 1·01 0·31 0·30 1·02 (0·87–1·20) 0·80
Testing uptake measured by proportion who reported HIV test; sexual risk behaviour measured by self-reported monthly number of unprotected sexual acts; social norms measured 
by scores ranging from 0 to 3, higher values corresponding to more favourable social norms; discussions about HIV measured by proportion who reported a discussion in the past 
month; disclosure of HIV status measured by proportion of tested participants who disclosed their last test result; stigma measured by scores ranging from 0 to 4, higher values 
corresponding to more stigma; negative life events measured by proportion who reported any events related to partnership break-up, discrimination, estrangement, neglect, or 
violence. CBVCT=community-based voluntary counselling and testing. SVCT=standard voluntary counselling and testing. NA=data not available. *Mean baseline ratio of CBVCT vs 
SVCT communities. †Intervention eﬀ ect, increase in mean CBVCT:SVCT ratio since baseline (except for testing uptake and disclosure, where the eﬀ ect is post-intervention 
assessment CBVCT:SVCT ratio). ‡p value for the hypothesis of no intervention eﬀ ect on outcome.
Table 6: Behavioural outcome results
Number of 
incident samples*
Incidence (%)† Intervention eﬀ ect‡ 
(95% CI)
p value§
CBVCT SVCT CBVCT SVCT
All participants 205 240 1·52% 1·81% 0·86 (0·73–1·02) 0·082
Analysis by sex
Women 142 161 2·06% 2·42% 0·88 (0·73–1·06) 0·17
Men 63 79 0·95% 1·19% 0·81 (0·57–1·15) 0·19
Analysis by age
18–24 years 125 134 1·65% 1·76% 0·98 (0·80–1·22) 0·86
25–32 years 80 105 1·38% 1·90% 0·75 (0·54–1·04) 0·078
Analysis by sex and age
Women, age 18–24 years 96 96 2·50% 2·55% 1·00 (0·78–1·28) 0·98
Men, age 18–24 years 29 38 0·76% 0·98% 0·95 (0·64–1·40) 0·69
Women, age 25–32 years 46 65 1·54% 2·29% 0·70 (0·54–0·90) 0·0085
Men, age 25–32 years 34 40 1·20% 1·46% 0·78 (0·41–1·47) 0·39
CBVCT=community-based voluntary counselling and testing. SVCT=standard voluntary counselling and testing. 
*The number of samples from HIV-positive individuals that were classiﬁ ed as multi-assay algorithm positive (excluding 
samples with antiretroviral drugs detected), and samples from HIV-positive individuals with acute or early infection. 
†Annual rate, calculated across the African sites. ‡Relative risk of HIV infection (CBVCT vs SVCT); weighted average of 
incidence ratios for 17 community pairs. §p value for the hypothesis of no intervention eﬀ ect on incidence.
Table 5: Incidence across all African sites
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present for treatment later in their illness and to die 
sooner from HIV than women. We believe that a Project 
Accept model that takes testing to the individual rather 
than having the person come to testing, might be 
important to test hard-to-reach populations such as men. 
To reach men in this way might have been important in 
the reductions in risk behaviour that we recorded in HIV-
positive men in the intervention communities.
In Project Accept we showed community-wide eﬀ ects 
from an intervention focused on mobilisation, testing, 
and support. The behavioural results were more 
signiﬁ cant than was the decrease in HIV incidence. 
Inclusion of accessible voluntary counselling and testing 
is likely to be a key component of an integrated 
combination approach to HIV prevention and care. 
Additionally, our data suggest that community-wide 
testing plus treatment programmes can be both safe and 
feasible. High testing rates are essential for any 
prevention strategy to be successful. Therefore, Project 
Accept sets a benchmark for assessment of success of 
continuing and future combination prevention trials that 
include a broader range of interventions, including 
increased provision of treatment for HIV.
This was the ﬁ rst cluster-randomised trial with stigma 
reduction as a secondary endpoint. However, stigma was 
low at baseline and had little room to decrease further, 
possibly because of social desirability bias. Similarly, a 
recent trial28 investigating changes in stigma through 
provision of home-based voluntary counselling and 
testing in Zambia showed no eﬀ ect and an overall 
reduction in stigmatising attitudes from baseline to 
follow-up. Further work is needed to adequately measure 
the eﬀ ect of stigma reduction eﬀ orts.
HIV incidence was estimated from a cross-sectional 
survey done at the end of the intervention period with a 
multi-assay algorithm developed and validated for this 
purpose. This was a novel approach in HIV prevention 
research. We were unable to measure baseline incidence 
or to use cohort follow-up to estimate incidence because 
these activities would have interfered with the study 
intervention. Therefore, we could not adjust for baseline 
HIV incidence or match the communities on HIV 
prevalence. Data from our validation studies suggest that 
the algorithm provided better precision than did 
6 months of cohort follow-up.22 Findings of the validation 
studies also showed that the multi-assay algorithm had a 
negligible bias for estimation of the intervention eﬀ ect, 
and provided valid tests and conﬁ dence intervals. The 
incidence estimates that we obtained were consistent 
with those reported in cohort studies done in regions 
with similar HIV prevalence.29 Use of ART was addressed 
by exclusion of infections from the incidence estimate if 
samples contained antiretroviral drugs.21
With the exception of the KwaZulu-Natal site, HIV 
incidence and prevalence at the African sites was lower 
than anticipated. Unfortunately the Thailand site had to 
be excluded because of very low prevalence. Much higher 
prevalence in Thailand was anticipated because of 
widespread injection drug use. In some communities, 
participation rates were lower than desired, which might 
have aﬀ ected outcomes. Complete information about 
the number of tests provided in both the intervention 
and control communities and the ability to track tests in 
these communities would have been helpful. In South 
Africa, no data for testing in the control communities 
were available and, at all sites, we could not gather data 
for all testing that took place. We had no control over the 
various approaches and alternative opportunities for 
HIV testing that might have been available, and, 
therefore, we had no alternative but to use self-reported 
testing data to ensure comparability. However, the self-
reports were collected from random probability samples 
of the community members who might have known that 
their community was part of a study. The data were 
collected by assessors who had no knowledge of the 
participant’s serostatus, thus reducing the potential for 
self-report bias.
Panel: Research in context
Systematic review
A thorough systematic review and meta-analysis of community-based voluntary HIV 
testing and counselling was published in August, 2013, by Suthar and colleagues.27 
Suthar and colleagues searched PubMed, clinical trial registries, Embase, and WHO Global 
Index Medicus with no restriction on date or language for studies that included 
community-based HIV testing and counselling. Search terms are listed in the appendix 
(appendix p 8). Randomised controlled trials and observational studies were eligible if they 
included a community-based testing approach and reported one or more of the following 
outcomes: uptake, proportion receiving their ﬁ rst HIV test, CD4 value at diagnosis, linkage 
to care, HIV positivity rate, HIV testing and counselling coverage, HIV incidence, or cost per 
person tested. Suthar and colleagues reviewed 11 community-based strategies for HIV 
testing and counselling. They used Newcastle-Ottawa Quality Assessment Scale and the 
Cochrane Collaboration’s risk of bias method to assess the risk of bias in studies with a 
comparator group included in pooled estimates. 117 studies including 864 651 participants 
completing HIV testing and counselling met the inclusion criteria. 
We also did separate searches for every secondary outcome that we studied. We searched 
PubMed for relevant experimental studies with no restriction on date or language. We 
searched for studies that used uptake of HIV testing as a primary or secondary outcome, 
with the following terms: (“HIV testing” OR “VCT”) AND (“utilization” OR “uptake”) AND 
(“trial” OR “intervention”). 
Interpretation
Many studies, including Project Accept, have documented substantial beneﬁ t associated 
with community-based counselling and testing for HIV. However, none have shown 
decreased HIV incidence and few have documented the eﬀ ects on special populations at 
risk (eg, men), HIV risk behaviour, and community social norms regarding HIV. Although 
many studies have tested the eﬀ ectiveness of interventions in the uptake of HIV testing, 
few experimental studies have tested the eﬀ ect of combined social, behavioural, and 
structural interventions to address barriers to HIV testing or change in community norms 
that lead to decreased HIV transmission. Additionally, this study adds to previous 
scientiﬁ c literature by assessing the eﬀ ects of the multi-component intervention at the 
level of an entire community as opposed to individuals recruited into a clinical trial. The 
appendix gives a more detailed interpretion of results (appendix p 9).
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Results of Project Accept show what is possible when 
multicomponent mobilisation, testing, and support 
services are implemented. Even if treatment as prevention 
is proven eﬀ ective, the likelihood of implementation in 
most jurisdictions is low. Our results are suﬃ  ciently 
robust, especially taking the primary and secondary 
outcomes together, to recommend a combination of 
mobilisation, mobile testing, post-test support services, 
and monitoring and assessment of service providers as 
routine components of public health practice. The results 
of Project Accept show that slight reductions in HIV 
incidence can be achieved with a multicomponent, 
multilevel social and behavioural intervention alone, 
without scale-up of other services and implementation of 
structural and biomedical interventions. Project Accept 
also showed an eﬀ ective method to increase HIV testing 
and reduce HIV risk behaviour. High testing rates are 
essential for any prevention strategy to be successful, and 
are an essential ﬁ rst step in the implementation of any 
strategy, especially treatment-as-prevention. Therefore, 
Project Accept sets a benchmark for assessment of success 
of continuing and future combination prevention trials 
that include a broad range of study interventions, including 
increased provision of ART. The judicious combination 
and application of behavioural, social, and biomedical 
interventions should achieve great reductions in HIV 
incidence in entire communities.
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